Cue Biotech, Inc. Enters Collaboration with Lundbeck to Discover Allosteric Modulators of G-Protein Coupled Receptors.EVANSTON, Ill. -- Cue Biotech, Inc. today announced a collaboration with H. Lundbeck A/S to discover and develop small molecule therapeutics targeting G-Protein Coupled Receptors, or GPCR GPCR Guanine Nucleotide-Binding Protein-Coupled Receptor GPCR GTP-binding Protein-Coupled Receptor , for disorders and diseases of the Central Nervous System (CNS See Continuous net settlement. CNS See continuous net settlement (CNS). ). The companies will apply Cue Biotech's Cue-Quest screening technology to multiple GPCR targets in their efforts to identify and develop novel small molecules that allosterically modulate To insert a data signal into a carrier wave or direct current. See modulation. important CNS targets. Under the terms of the agreement, Cue Biotech will receive R&D payments with the potential for additional payments based on the success of the programs. Scientists from Cue Biotech and Lundbeck will work together to select the GPCR targets for screening and Lundbeck will be responsible for preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. and clinical development of the results of the collaboration. "Lundbeck is excited to explore the Cue technology hands-on. It is very complementary to our own areas of focus. We have followed Cue's development for several years and are impressed by their scientific leadership and accomplishments" said Dr. Peter Hongaard Andersen, Vice President, Head of Research, H. Lundbeck A/S. "A strong partnership with Lundbeck provides Cue Biotech with an exciting opportunity to apply its proprietary approach to GPCR-targeted drug discovery to the CNS space with an industry leader in this therapeutic area," said Dr. Annette Gilchrist, President and CSO (Chief Security Officer) The person in charge of all staff members who are responsible for promulgating, enforcing and administering security policies for all systems within an enterprise or division. , Cue Biotech, Inc. About Cue Biotech, Inc. Cue Biotech, Inc. is a leader in G-protein coupled receptors. The Company integrates its research expertise in this area with its systematic approach to the identification of small molecule allosteric allosteric /al·lo·ster·ic/ (al?o-ster´ik) pertaining to allostery. allosteric pertaining to an effect on the biological function of a protein, produced by a compound not directly involved in that function (an allosteric modulators using its proprietary high-throughput assay. The Company is building its own portfolio of GPCR-targeted novel drug leads for licensing to biopharmaceutical companies, and to date has established agreements with various industry leaders. Cue Biotech, Inc. is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. based in Evanston, IL. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion